Predictors of Human Papillomavirus Vaccination in a Large Clinical Population of Males Aged 11 to 26 years in Maryland, 2012-2013

about

Predictors of Human Papillomavirus Vaccination in a Large Clinical Population of Males Aged 11 to 26 years in Maryland, 2012-2013

Item

http://www.wikidata.org/entity/Q36619758

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@ast

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@en

type

Item

label

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@ast

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@en

prefLabel

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@ast

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@en

P1476

Predictors of Human Papillomav ...... 6 years in Maryland, 2012-2013

@en

P2093

Betty Chou

http://www.w3.org/2001/XMLSchema#string

Corinne E Joshu

http://www.w3.org/2001/XMLSchema#string

Darcy F Phelan-Emrick

http://www.w3.org/2001/XMLSchema#string

Francesca Coutinho

http://www.w3.org/2001/XMLSchema#string

MaryAnn Wilbur

http://www.w3.org/2001/XMLSchema#string

Megan A Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Factors affecting human papillomavirus vaccine use among White, Black and Latino parents of sons.

Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

P304

351-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1055-9965.EPI-15-0983

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26698909

http://www.w3.org/2001/XMLSchema#string

P932

4767642

http://www.w3.org/2001/XMLSchema#string